[Severe acute pancreatitis in children receiving asparaginase: multicenter retrospective study].
Asparaginase is frequently used in the treatment of lymphoblastic malignancies in children and is a major cause of drug-induced acute pancreatitis. Severe cases of iatrogenic pancreatitis are uncommon but potentially lethal, and represent a diagnostic and therapeutic challenge.


METHODS
We have retrospectively collected pediatric cases of severe acute pancreatitis induced by asparaginase, having occurred since January 1996 in participating centers from France and Belgium.


RESULTS
Eleven patients, between four and 15 years old, have been included. Pancreatitis has been observed in all treatment phases, after 6 to 21 doses of asparaginase, 2 to 16 days after the last injection. Circulatory collapse (5/11), insulin-dependent diabetes (6/11) and pancreatic pseudokysts (7/11) were the major complications. Non-surgical treatment mainly included digestive rest, broad-spectrum antibiotic therapy and prolonged use of morphine. Asparaginase has been eventually reintroduced in three cases, and has caused a recurrence of pancreatitis in two of them.


CONCLUSIONS
Intensive supportive management should enable a favourable outcome in most cases of acute pancreatitis induced by asparaginase in children. There is no way to predict the occurrence of this adverse event. Re-use of asparaginase should probably be ruled out.
Laugel
V
V
Service d'oncohématologie pédiatrique, hôpital de Hautepierre, CHU de Strasbourg, avenue Molière, 67098 Strasbourg cedex, France.
Escande
B
B
Entz-Werle
N
N
Mazingue
F
F
Ferster
A
A
Bertrand
Y
Y
Missud
F
F
Lutz
P
P
D000208:Acute Disease; D000293:Adolescent; D001215:Asparaginase / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D010195:Pancreatitis / Q000139:chemically induced* / Q000628:therapy; D012189:Retrospective Studies; D012720:Severity of Illness Index
D001215:Asparaginase